Sec. 514. Policy statement on medical discovery, development, delivery, and innovation
263 words·~1 min read·
/bill/115/hconres/71/rh/section-514·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The House finds the following: The Nation’s commitment to the discovery, development, and delivery of new treatments and cures has made the United States the biomedical innovation capital of the world for decades. The history of scientific discovery and medical breakthroughs in the United States is extensive, including the creation of the polio vaccine, the first genetic mapping, and the invention of the implantable cardiac pacemaker. Reuters ranks the United States Health and Human Services Laboratories as first in the world for innovation on its 2017 list of the Top 25 Global Innovators.
The United States leads the world in the production of medical devices, and the United States medical device market accounts for approximately 45 percent of the global market. The United States remains a global leader in pharmaceutical research and development investment, has produced more than half of the world’s new molecules in the past decade, and represents the world’s largest pharmaceutical market, which is triple the size of the nearest rival, China. It is the policy of this concurrent resolution that— the Federal Government should foster investment in health care innovation and maintain the Nation’s world leadership status in medical science by encouraging competition; the House should continue to support the critical work of medical innovators throughout the country through continued funding for agencies, including the National Institutes of Health and the Centers for Disease Control and Prevention, to conduct life-saving research and development; and the Federal Government should unleash the power of private-sector medical innovation by removing regulatory obstacles that impede the adoption of new medical technology and pharmaceuticals.